Balance Sheet

Cash Flow Statement

Acquisitions Amortization of Goodwill Amortization of Goodwill Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Cash from Restructuring Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Taxes Change in Taxes Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Divestments Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased

Daily Values

Growth Metrics

Others

Anika Therapeutics (ANIK) Amortization of Deferred Charges (2019 - 2021)

Anika Therapeutics has reported Amortization of Deferred Charges over the past 3 years, most recently at $400000.0 for Q3 2021.

Quarterly Amortization of Deferred Charges fell 2.68% to $400000.0 in Q3 2021 from the year-ago period, while the trailing twelve-month figure was $1.7 million through Sep 2021, up 18.95% year-over-year, with the annual reading at $1.5 million for FY2020, 29.86% up from the prior year.
Amortization of Deferred Charges was $400000.0 for Q3 2021 at Anika Therapeutics, down from $507000.0 in the prior quarter.
Over five years, Amortization of Deferred Charges peaked at $507000.0 in Q2 2021 and troughed at $289000.0 in Q3 2019.
The 3-year median for Amortization of Deferred Charges is $385000.0 (2020), against an average of $365636.4.
Year-over-year, Amortization of Deferred Charges skyrocketed 42.21% in 2020 and then fell 2.68% in 2021.
A 3-year view of Amortization of Deferred Charges shows it stood at $299000.0 in 2019, then surged by 32.11% to $395000.0 in 2020, then grew by 1.27% to $400000.0 in 2021.
Per Business Quant, the three most recent readings for ANIK's Amortization of Deferred Charges are $400000.0 (Q3 2021), $507000.0 (Q2 2021), and $405000.0 (Q1 2021).